Calistoga Pharmaceuticals

In Frazier Healthcare Ventures portfolio

News: Lead drug CAL-101 is said to kill tumor cells (Dec. 9, 2008)

HealthCare Ventures

HealthCare Ventures

Click here to see this fund’s portfolio.

Alnylam Pharmaceuticals (ALNY)

Core Competency: RNAi interference

Alliances: Novartis, Roche, Takeda

News: Purchased 116 pieces of IP from Nucleonics (Dec. 8, 2008)  Looks like Alnylam is making a move to cluster and consolidate its presence in the RNAi space in terms of IP positioning.

RNAi platforms seem to be all the rage right now, so such a move seems a strong strategic advance for the Cambridge, MA company.

Seattle Genetics

SGN-35.  Targeted antibody that identifies CD-30 and dumps a lethal dose of chemotherapy into tumor cells.